Keywords: Spectrum Pharma, Viropro, Roche, Rituximab, Actemra

Spectrum Pharma links with Viropro to develop biosimilar of Roche blockbuster drug rituximab; FDA expands use of Roche’s Actemra

Article | 06 January 2011

Print This

USA-based biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) says that it has signed a letter of agreement with Viropro (VPRO: OTC ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in